2月11日，国务院以"深化拓展'人工智能+'、全方位赋能千行百业"为主题，举行第十八次专题学习。会 议指出，"人工智能+"前景广阔，将不断带动消费和产业升级，在各个领域打开新的增量空间。 这一高层定调为AI医疗行业注入强劲发展动力，医渡科技长期深耕的赛道契合"人工智能+医疗健康"的 核心赋能方向，其持续回购行为也成为对行业趋势的积极回应。 智通财经APP获悉，2月12日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.95港元的 价格回购约56万股，总耗资超330万港元，实现连续第14个交易日密集回购，累计回购金额已突破6400 万港元，以连贯稳健的资本动作，持续传递对自身价值与行业前景的双重信心。 业务端的突破进一步夯实回购底气：近日，医渡科技与华中科技大学同济医学院附属同济医院(下称"同 济医院")联合申报的胃肠肿瘤诊疗多模态AI数据库项目成功入选国家工信部2025年人工智能医疗器械创 新任务"揭榜挂帅"名单。作为国家为加速关键核心技术攻关、推动科技成果转化设立的重大创新机 制，"揭榜挂帅"名单的入选，既彰显了其在AI医疗领域的硬实力，也印证了其业务布局与国家战略需求 的高度契合，为公司在 ...

智通财经APP讯，医渡科技(02158)公布，2026年2月12日耗资332.25万港元回购55.8万股股份。 ...

Group 1 - The company, Yidu Tech (02158), announced a share buyback of 558,000 shares at a cost of HKD 3.3225 million on February 12, 2026 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Company Summary - Yidu Tech (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Yidu Tech achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's "2025 Artificial Intelligence Medical Device Innovation Task" list with a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting that 2026 will likely see greater certainty in AI medical commercialization and open up new commercial opportunities [1][1][1] - Key areas to focus on include AI pharmaceuticals, grassroots AI medical applications, medical data circulation and trading, AI pathological diagnosis, AI medical models, and C-end expansion channels, along with related targets [1][1][1]

Company Summary - Medicure Technology (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Medicure Technology achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's 2025 AI medical device innovation project list with a multimodal AI database project for gastrointestinal tumor diagnosis and treatment in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting a stronger certainty for AI medical commercialization in 2026 [1][1][1] - Key areas for investment focus include AI drug development, grassroots AI medical applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1][1][1]

医渡科技(02158)发布公告，于2026年2月11日斥资290.62万港元回购48.6万股。 ...

格隆汇2月11日丨医渡科技(02158.HK)公告，2月11日耗资290.6万港元回购48.6万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月11日斥资290.62万港元回购48.6万股。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...